Mammatyper Seen to Ably Classify Invasive Breast Cancers, Key to Proper Treatment

Mammatyper Seen to Ably Classify Invasive Breast Cancers, Key to Proper Treatment
BioNTech Diagnostics reports that data supporting the superiority of a device called the MammaTyper in classifying newly diagnosed invasive breast cancer has been confirmed by a recently published study. The study, Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry, published in the journal Breast Cancer Research and Treatmentcompared the device, building on analyses of mRNA, with current practices allowing trained pathologists to analyze tumor tissue samples under the microscope. Knowledge of how levels of various proteins expressed in breast cancer tissue correlate with such concerns as response to treatment and prognosis has allowed scientists to segregate breast cancer into several distinct subtypes, in what is known as the St. Gallen classification. According to this system, tumors can be classified into five types referred to as luminal A-like, luminal B-like (HER2 negative), luminal B-like (HER2 positive), HER2 positive (non-luminal) and triple negative (ductal) tumors. Traditionally, the work to detect and quantify the levels of the protein markers characterizing a tumor's subtype has been the job of a trained pathologist, analyzing tissue samples under the microscope. But such analysis can often be imprecise, leading to suboptimal care for cancer patients. The Mammatyper builds on an established technique to quantify the levels of messenger RNA, acting as an intermediate step between gene and protein. BioNTech has refined the method to specif
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.